Mallinckrodt debuts MR contrast injectors
Mallinckrodt has begun selling its Optistar MR contrast power injectors in the U.S. following FDA clearance of the device in December. Optistar is also being sold in Canada. St. Louis-based Mallinckrodt, which is working to become a single-source
Mallinckrodt has begun selling its Optistar MR contrast power injectors in the U.S. following FDA clearance of the device in December. Optistar is also being sold in Canada. St. Louis-based Mallinckrodt, which is working to become a single-source supplier for the contrast imaging market, estimates the annual market for power injectors to be around $35 million.
In related news, Mallinckrodt management is expanding its share repurchase program during the balance of this fiscal year (end-June) due to recent weakness in the companys stock price. So far this fiscal year, the company has repurchased 2.8 million shares of its stock at a market value of $90 million.